Tools
ToolsMerinopoulos, Ioannis, Bhalraam, U., Gunawardena, Tharusha, Corballis, Natasha, Natarajan, Rajkumar, Wickramarachchi, Upul, Maart, Clint, Sreekumar, Sulfi, Sawh, Chris, Reinhold, Johannes, Wistow, Trevor, Ryding, Alisdair, Gilbert, Timothy, Vassiliou, Vassilios S. and Eccleshall, Simon C. (2025) Assessment of paclitaxel drug-coated balloon-only angioplasty for stent thrombosis: SPARTAN-ST study. Journal of Cardiovascular Development and Disease, 12 (2). ISSN 2308-3425
Preview |
PDF (jcdd-12-00059)
- Published Version
Available under License Creative Commons Attribution. Download (910kB) | Preview |
Abstract
Background: There are no data regarding the outcomes of patients with stent thrombosis (ST) being treated with drug-coated balloon (DCB) angioplasty. Our aim was to compare the outcomes of patients with ST treated with DCB vs. a drug eluting stent (DES). Methods: In this registry analysis, we identified all patients treated for ST in our institution from June 2011 until November 2019. We excluded patients who died in the cath lab, patients with uncrossable lesions, and patients treated with thrombectomy only. Patient outcomes were obtained from Hospital Episodes Statistics from NHS England. The primary endpoint of this study was the composite of cardiovascular mortality, acute coronary syndrome, or target lesion revascularisation. The data were analysed with Cox regression and Kaplan–Meier estimator plots. Results: A total of 173 patients were identified; 92 treated with DCB-only, 36 with balloon angioplasty (BA), 26 with DES, and 19 with a combination of DES and DCB. We compared the outcomes of 92 patients with DCB versus 20 patients with DES, all of which had presented with late or very late ST. There was no difference between DCB and DES in terms of the primary endpoint (p = 0.06). Multivariate analysis identified diabetes (adverse) and the use of GPIIbIIIa inhibitor (favourable) as the only independent predictors of the primary endpoint. Implantation of a DES was independently associated with worse cardiovascular mortality. Conclusions: This is the first study assessing the outcomes of patients with ST treated with DCB only. It has demonstrated that DCBs are an attractive therapeutic option with a tendency towards favourable outcomes when compared to DESs.
| Item Type: | Article |
|---|---|
| Additional Information: | Data Availability Statement: The data are available following appropriate request to the authors. Funding Information: This is an investigator-initiated study partially supported by B Braun and Cordis. Dr Corballis and Dr Bhalraam are NIHR Academic Clinical Fellows. |
| Uncontrolled Keywords: | dcb,stent thrombosis,pharmacology, toxicology and pharmaceutics(all),pharmacology (medical) ,/dk/atira/pure/subjectarea/asjc/3000 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 02 Jul 2025 08:30 |
| Last Modified: | 02 Jul 2025 08:30 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/99797 |
| DOI: | 10.3390/jcdd12020059 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |